U.S. market Closed. Opens in 1 day 11 hours 31 minutes

BRTX | BioRestorative Therapies, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.4200 - 1.5500
52 Week Range 1.0300 - 3.67
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 15,763
Average Volume 49,073
Shares Outstanding 6,919,920
Market Cap 10,725,876
Sector Healthcare
Industry Biotechnology
IPO Date 2012-12-05
Valuation
Profitability
Growth
Health
P/E Ratio -0.65
Forward P/E Ratio N/A
EPS -2.38
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 11
Country USA
Website BRTX
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
*Chart delayed
Analyzing fundamentals for BRTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see BRTX Fundamentals page.

Watching at BRTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BRTX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙